Not checked for notices yet.

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey and 11 more

Journal for ImmunoTherapy of Cancer · 2019

doi:10.1186/s40425-019-0510-7

References 26

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer · 2008
No notice
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles · 2012
No notice
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies · 2017
No notice
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection · 2017
No notice
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 4

Exploring treatment options in cancer: tumor treatment strategies · 2024
No notice
Oncolytic virotherapy: basic principles, recent advances and future directions · 2023
No notice
Oncolytic viruses for cancer immunotherapy · 2020
No notice
Gene Therapy Leaves a Vicious Cycle · 2019
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.